Abstracts tagged "clinical trial"

Abstract Number: 2035 • ACR Convergence 2020
Exploring Stratification Strategies for Early Diffuse Systemic Sclerosis Clinical Trial Design
Robyn Domsic¹, Shiyao Gao², Maureen Laffoon², Steven Wisniewski³, Robert Lafyatis⁴, Virginia Steen⁵ and Thomas Medsger⁶, ¹University of Pittsburgh School of Medicine, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA, ³University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, ⁴University of Pittsburgh, Arlington, MA, ⁵Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, ⁶University of Pittsburgh School of Medicine, Verona, PA
Background/Purpose: Clinical trials in early diffuse systemic sclerosis (SSc) using the modified Rodnan skin score (mRSS) as the primary outcome have been largely negative. This…
Abstract Number: 0107 • ACR Convergence 2020
Effects of Abaloparatide on Modeling and Remodeling Based Bone Formation
David W Dempster¹, Hua Zhou¹, Sudhaker D Rao², Chris Recknor³, Paul D Miller⁴, Benjamin Z Leder⁵, Miriam Annett⁶, Michael S Ominsky⁶ and Bruce H Mitlak⁶, ¹Regional Bone Center, Helen Hayes Hospital, West Haverstraw, NY, West Haverstraw, NY, ²Bone & Mineral Research Laboratory, Henry Ford Health System, Detroit, MI, Detroit, MI, ³United Osteoporosis Centers, Gainesville, GA, Gainesville, GA, ⁴Colorado Center for Bone Research, Lakewood, CO, Lakewood, CO, ⁵Mass General Hospital, Harvard Medical School, Boston, MA, Boston, MA, ⁶Radius Health, Inc., Waltham, MA, Waltham, MA
Background/Purpose: To evaluate abaloparatide-induced changes in the bone formation indices of mineralizing surface (MS), bone formation rate (BFR) and mineral apposition rate (MAR); and to…
Abstract Number: 0215 • ACR Convergence 2020
Incidence and Risk of Venous Thromboembolic Events Among Patients with Rheumatoid Arthritis Enrolled in the Upadacitinib Clinical Trial Program
Ernest Choy¹, Iain McInnes², John Cush³, Jacob Aelion⁴, William Rigby⁵, Yanna Song⁶, Sebastian Meerwein⁷, John Liu⁸, Nasser Khan⁸, Jessica Suboticki⁸ and Alexander Cohen⁹, ¹CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom, ²Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ³University of Texas Southwestern Medical School, Dallas, TX, ⁴Arthritis Clinic PLLC, Jackson, ⁵Dartmouth College, Norwichi, VT, ⁶AbbVie Inc., North Chicago,, IL, ⁷Pharmaceutical Development, AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany, ⁸AbbVie Inc., North Chicago, IL, ⁹Guy’s and St Thomas’ NHS FT Hospitals, King’s College, London, United Kingdom
Background/Purpose: Patients (pts) with rheumatoid arthritis (RA) are at an increased risk for the development of venous thromboembolism (VTE, including pulmonary embolism [PE] and deep…
Abstract Number: 0385 • ACR Convergence 2020
A Pilot Study to Evaluate the Safety and Efficacy of Treprostinil in the Treatment of Calcinosis in Patients with Systemic Sclerosis
Melody Chung¹, Antonia Maria Valenzuela Vergara², Benjamin Catanese¹, Shufeng Li¹, Kate Stevens¹ and Lorinda Chung³, ¹Stanford University, Stanford, CA, ²Pontificia Universidad Catolica de Chile, Santiago de Chile, Chile, ³Stanford University School of Medicine and Palo Alto VA Health Care System, Palo Alto, CA
Background/Purpose: Calcinosis is characterized by calcium deposition in skin and subcutaneous tissues and progresses over one year in the majority of systemic sclerosis (SSc) patients. Since…
Abstract Number: 0800 • ACR Convergence 2020
A Randomized, Double-Blind, Phase 3 Study to Compare the Efficacy and Safety of a Proposed High Concentration (100 mg/mL) Adalimumab Biosimilar (CT-P17) with Reference Adalimumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis
Jonathan Kay¹, Janusz Jaworski², Rafal Wojciechowski³, Piotr Wiland⁴, Anna Dudek⁵, Marek Krogulec⁶, Slawomir Jeka⁷, Agnieszka Zielinska⁸, Jakub Trefler⁹, Katarzyna Bartnicka-Maslowska¹⁰, Magdalena Krajewska-Wlodarczyk¹¹, Piotr Klimiuk¹², Daniel Furst*¹³, SangJoon Lee¹⁴, YunJu Bae¹⁴, GoEun Yang¹⁴, JaeKyoung Yoo¹⁴, HyunJin Lee¹⁴ and Edward C Keystone¹⁵, ¹University of Massachusetts Medical School, Worcester, MA, ²Reumatika-Centrum Reumatologii, Warsaw, Poland, ³University Hospital No 2, Bydgoszcz, Poland, ⁴Medical Univeristy, Wroclaw, Poland, ⁵Centrum Medyczne AMED, Warsaw, Poland, ⁶Rheumatology Clinic NZOZ Lecznica MAK-MED, Nadarzyn, Poland, ⁷2nd Univ Hospital, CM UMK, Bydgoszcz, Poland, ⁸Medycyna Kliniczna Marzena Waszczak-Jeka, Warsaw, Poland, ⁹Reuma Centrum, Warsaw, Poland, ¹⁰Centrum Medyczne AMED oddzial w Łodzi, Łódź, Poland, ¹¹University of Warmia and Mazury, Olsztyn, Poland, ¹²Medical University of Białystok and Gabinet Internistyczno-Reumatologiczny Piotr Adrian Klimiuk, Białystok, Poland, ¹³Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA, Los Angeles, CA, ¹⁴Celltrion, Inc., Incheon, Republic of Korea, ¹⁵Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: CT-P17 (100 mg/mL) is the first proposed biosimilar of the high concentration and citrate-free formulation of reference adalimumab. The purpose of this study was…
Abstract Number: 0952 • ACR Convergence 2020
Reducing Immunogenicity of Pegloticase (RECIPE) with Concomitant Use of Mycophenolate Mofetil in Patients with Refractory Gout—a Phase II Double Blind Randomized Controlled Trial
Puja Khanna¹, Dinesh Khanna¹, Gary Cutter², Jeffrey Foster², Joshua Melnick³, Sara Jaafar¹, Stephanie Biggers², AKM Rahman², Hui-Chen Kuo², Michelle Feese² and Kenneth Saag⁴, ¹University of Michigan, Ann Arbor, MI, ²University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham (UAB), Vestavia Hills, AL, ⁴University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL
Background/Purpose: Pegloticase, a recombinant, pegylated uricase, is used for treatment of gout in patients who fail oral urate lowering therapy (ULT). Despite successful reduction of…
Abstract Number: 1238 • ACR Convergence 2020
Associations Between Rheumatoid Arthritis Disease Activity and Patient-reported Outcomes in Sarilumab Clinical Trials
Gerd Burmester¹, Laure Gossec², Hubert van Hoogstraten³, Amy Praestgaard⁴, Gregory St John⁵, Thomas Huizinga⁶, Daniel Aletaha⁷ and Roy Fleischmann⁸, ¹Charité University Hospital Berlin, Berlin, Germany, ²Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France, ³Sanofi, Bridgewater, NJ, ⁴Sanofi, Cambridge, MA, ⁵Regeneron Pharmaceuticals Inc, Tarrytown, NY, ⁶Leiden University Medical Center, Leiden, Netherlands, ⁷Division of Rheumatology, Department of Medicine III, Medical University of Vienna,, Vienna, Austria, ⁸Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: Sarilumab is a human IL-6 receptor inhibitor approved for the treatment of adults with moderately to severely active RA. The relationship between disease activity,…
Abstract Number: 1747 • ACR Convergence 2020
Brain fMRI Predicts Responses to Certolizumab Pegol in RA. an International, Multi-center, Randomized, Double-blind, Placebo-controlled Trial (PreCePRA)
Juergen Rech¹, Hannah Schenker², Koray Tascilar¹, Melanie Hagen², Arnd Kleyer¹, David Simon¹, Larissa Valor Mendez², Verena Schoenau³, Jutta Prade⁴, Marina Sergeeva⁴, Mageshvar Sulvakumar⁵, Sandra Strobelt⁴, Laura Konerth⁴, Frank Behrens⁶, Christoph Baerwald⁷, Stephanie Finzel⁸, Reinhard Voll⁹, Axel Hueber¹⁰, Julie Roesch¹¹, Eugen Feist¹², José A. P. da Silva¹³, Arnd Doerfler¹¹, Nemanja Damjanov¹⁴, Andreas Hess¹⁵ and Georg Schett¹⁶, ¹Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, ²Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054, Erlangen, Germany, Erlangen, Germany, ³Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054, Erlangen, Germany, Erlangen, ⁴Institute for Experimental Pharmacology, Erlangen, Germany, ⁵Insitute for Experimental Pharmacology , Fau Erlangen-Nürnberg, Erlangen, Germany, ⁶CIRI/Rheumatology & Fraunhofer TMP, Goethe University, Frankfurt, Germany, ⁷Uniklinik Leipzig, Medizinische Klinik III - Bereich Rheumatologie, Leipzig, Germany, ⁸Universitätsklinikum Freiburg, Klinik für Rheumatologie und Klinische Immunologie, Freiburg, Germany, ⁹Universitätsklinikum Freiburg, Klinik für Rheumatologie und Klinische Immunologie, Freibrug, ¹⁰Section Rheumatology, Sozialstiftung Bamberg, Bamberg, Germany, ¹¹Abteilung für Neuroradiologie, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054, Erlangen, Germany, Erlangen, Germany, ¹²Department of Rheumatology, Helios Vogelsang-Gommern, Vogelsang-Gommern, Germany, ¹³9.Centro Hospitalar e Universitário Coimbra (Rheumatology Department), Coimbra, Portugal, Coimbra, Portugal, ¹⁴University of Belgrade Medical School, Belgrade, Serbia, ¹⁵Institute for Experimental Pharmacology, Erlangen, ¹⁶Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany
Background/Purpose: Personalization of RA treatment is not optimal due to lack of predictors. We previously demonstrated in RA patients that central nervous system (CNS) pain…
Abstract Number: 2052 • ACR Convergence 2020
Extended Follow-Up of Patients Recruited to a Randomized, Controlled Trial of Rituximab versus Azathioprine After Induction of Remission with Rituximab for Patients with ANCA-Associated Vasculitis and Relapsing Disease
Rona Smith¹, David Jayne² and Peter A. Merkel³, ¹University of Cambridge, Cambridge, United Kingdom, ²Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Cambridge, United Kingdom, ³Division of Rheumatology University of Pennsylvania, Philadelphia, PA
Background/Purpose: Rituximab is an effective therapy for induction of remission in ANCA-associated vasculitis (AAV). However, the effect of rituximab is not sustained, and subsequent relapse…
Abstract Number: 0136 • ACR Convergence 2020
Filgotinib Significantly Improved Patient-reported Health-related Quality of Life for Patients with Active Rheumatoid Arthritis: A Post Hoc Analysis of SF-36 and HAQ-DI from Phase 3 Studies
Clifton Bingham III¹, David Walker², Peter Nash³, Susan Lee⁴, Lei Ye⁴, Hao Hu⁴, Javaria Mona Khalid⁵ and Bernard Combe⁶, ¹Johns Hopkins University, Baltimore, MD, ²Northumbria Healthcare NHS Foundation Trust, North Shields, United Kingdom, ³School of Medicine Griffith University, Brisbane, Queensland, Australia, ⁴Gilead Sciences, Inc., Foster City, CA, ⁵Galapagos BV, Leiden, Netherlands, ⁶University of Montpellier, Montpellier, France
Background/Purpose: Reduction in pain and fatigue, maintenance of physical functioning, and improvement in health-related quality of life (HRQoL) are vital aspects of successful treatment for…
Abstract Number: 0220 • ACR Convergence 2020
Impact of Concomitant Glucocorticoids on the Clinical Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: An Ad Hoc Analysis of Data from Three Phase 3 Studies
Bernard Combe¹, Frank Buttgereit², Andrew Östör³, Ricardo Xavier⁴, Alain Saraux⁵, Capucine Daridon⁶, Kirsten Famulla⁷, Yanna Song⁸, Ivan Lagunes-Galindo⁹ and Gerd Burmester¹⁰, ¹University of Montpellier, Montpellier, France, ²Charité University Medicine, Berlin, Germany, ³Cabrini Medical Center, Monash University, Malvern, Victoria, Australia, ⁴Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Rio Grande do Sul, Rio Grande do Sul, Brazil, ⁵Department of Rheumatology, UBO, CHU, INSERM 1227 (LBAI), Brest, France, ⁶AbbVie France, Rungis, France, ⁷AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁸AbbVie Inc., North Chicago,, IL, ⁹AbbVie Inc., North Chicago, IL, ¹⁰Charité University Hospital Berlin, Berlin, Germany
Background/Purpose: Glucocorticoid (GC) therapy has strong anti-inflammatory effects and helps slow radiographic progression in RA1; however, GCs can be associated with adverse events (AEs) such…
Abstract Number: 0386 • ACR Convergence 2020
Phase 1 Clinical Study of MGTA-145 in Combination with Plerixafor Shows Rapid Single-Day Mobilization and Collection of CD34+ Hematopoietic Stem Cells Without G-CSF
John DiPersio¹, Jonathan Hoggatt², Steven Devine³, David Scadden², Haley Howell⁴, Veit Schmelmer⁴, Glen Raffel⁴, Pat Falahee⁴, Kevin Goncalves⁴, William Savage⁴ and John Davis⁴, ¹Washington University, Saint Louis, ²Massachusetts General Hospital, Boston, ³National Marrow Donor Program, Minneapolis, ⁴Magenta Therapeutics, Cambridge
Background/Purpose: Autologous hematopoietic stem cell (HSC) transplantation is a recommended therapeutic option for selected patients with scleroderma and other autoimmune diseases. HSC transplant requires collection…
Abstract Number: 0811 • ACR Convergence 2020
Long-term Opioid Use in Patients with Rheumatoid Arthritis Treated with Sarilumab
Janet Pope¹, Amy Praestgaard², Hubert van Hoogstraten³, Melitza Iglesias-Rodriguez², Serge Perrot⁴, Yvonne Lee⁵, Anthony Sebba⁶ and Ernest Choy⁷, ¹Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, ²Sanofi, Cambridge, MA, ³Sanofi, Bridgewater, NJ, ⁴Paris Descartes University, Paris, Ile-de-France, France, ⁵Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Arthritis Associates, Palm Harbor, Tampa, FL, ⁷CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom
Background/Purpose: Prescription opioids are routinely used in patients with RA. However, use of opioids should be minimized to prevent abuse and addiction. Chronic opioid use…
Abstract Number: 0958 • ACR Convergence 2020
Tocilizumab in Myositis: Results of a Phase IIb Double-Blind Randomized Controlled Trial
Rohit Aggarwal¹, Howard Rockette², Swamy Venturupalli³, Galina Marder⁴, Mazen Dimachkie⁵, David Gazeley⁶, Floranne C. Ernste⁷, Leslie Crofford⁸, Siamak Moghadam-Kia⁹, Diane Koontz⁹, Lei Zhu¹ and Chester Oddis¹⁰, ¹University of Pittsburgh, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, ³Cedars Sinai Medical Center, Los Angeles, ⁴Northwell, New York, ⁵Univeristy of Kansas, Medical Center, Kansas City, KS, ⁶Medical College of Wisconsin, Wauwatosa, WI, ⁷Mayo Clinic, Rochester, ⁸Vanderbilt University Medical Center, Nashville, ⁹University of Pittsburgh Medical Center, Pittsburgh, PA, ¹⁰Department of Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: To assess the efficacy and tolerability of tocilizumab (anti-IL-6R, TCZ), in a multi-center, randomized, double blind, placebo-controlled trial in refractory adult dermatomyositis (DM) and…
Abstract Number: 1342 • ACR Convergence 2020
Efficacy Outcomes Following Etanercept Withdrawal by Sustained Remission Status in Patients with Nr-axSpA: Results from RE-EMBARK
Filip Van den Bosch¹, Peter Nash², James Cheng-Chung Wei³, Francisco Blanco⁴, Vassilis Tsekouras⁵, Chuanbo Zang⁶, Daniela Graham⁷, Edmund Arthur⁸, Pamela Selema⁶, Bonnie Vlahos⁶ and Atul Deodhar⁹, ¹Ghent University Hospital, Ghent, Belgium, ²School of Medicine Griffith University, Brisbane, Queensland, Australia, ³Chung Shan Medical University Hospital, Taichung, Taiwan (Republic of China), ⁴INIBIC-Complejo Hospitalario Universitario A Coruña, A Coruna, Spain, ⁵Pfizer, Nicosia, Cyprus, ⁶Pfizer, Collegeville, PA, ⁷Pfizer, Groton, PA, ⁸Pfizer, Peapack, NJ, ⁹Oregon Health & Science University, Portland, OR
Background/Purpose: Etanercept (ETN) is effective and well tolerated in patients with non-radiographic axial spondyloarthritis (nr-axSpA). However, there is limited information on the effects of withdrawing…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].